Having selected the optimal model after the hypothesis testing and practical considerations, we proceeded to develop it further, train it, and internally and externally validate it for potential application in risk estimation of bone metastasis in newly diagnosed prostate cancer patients using PSA, serum ALP, ISUP grade, and DRE-based clinical risk classification. This evidence concerns the gene KLK3 and prostate cancer.